Artiva Biotherapeutics (ARTV) EBT Margin (2023 - 2024)
Artiva Biotherapeutics (ARTV) posted quarterly EBT Margin of 5514.74% for Q1 2024, down 1017.11% quarter-over-quarter from 493.66% in Q4 2023.
Powered by 
Analysis
Artiva Biotherapeutics (ARTV) EBT Margin (2023 - 2024) Analysis & Trends
Artiva Biotherapeutics (ARTV) has reported EBT Margin for 2 consecutive years, with 5514.74% the latest figure, recorded in Q1 2024.
- In Q1 2024, EBT Margin changed N/A year-over-year to 5514.74%; the TTM figure through Dec 2024 stood at 39402.39% (changed N/A YoY), while the FY2024 annual figure was 26045.02%, down 2595948.0% from the prior year.
- EBT Margin fell to 5514.74% in Q1 2024 per ARTV's latest filing, from 493.66% in the prior quarter.
- Across five years, EBT Margin topped out at 42.13% in Q3 2023 and bottomed at 5514.74% in Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Artiva Biotherapeutics | 441.23 Mn | 441.23 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | -5,514.74% |
| Dec 31, 2023 | -484.55% |
| Sep 30, 2023 | 42.13% |
| Jun 30, 2023 | -323.56% |